. Author manuscript; available in PMC: 2018 Jan 18.

Published in final edited form as: Ann Surg Oncol. 2011 Jun 17;18(13):3544–3550. doi: 10.1245/s10434-011-1818-9

Table 5.

Frequency of selected protocol features among “successful” or “modestly successful” (for accrual of AA and/or HA; n=8) versus “unsuccessful” (for accrual of both AA and HA; n=3) with regard to accrual diversity

Feature		Proportion (%) of protocols with selected feature that were “successful” or “modestly successful”	Proportion (%) of protocols with selected feature that were “unsuccessful”
Protocol Design	Randomized n=4	3/4 (75%)	1/4 (25%)
Protocol Design	Not Randomized n=6	5/6 (83%)	1/6 (17%)
Protocol Eligibility	Early stage disease n=8	6/8 (75%)	2/8 (25%)
Protocol Eligibility	Regional or locally advanced disease n=2	2/2 (100%)	0/2 (0%)
Protocol Features	Investigational systemic therapy plus surgery n=3	3/3 (100%)	0/3 (0%)
Protocol Features	Primary surgical study n=7	5/7 (71%)	2/7 (29%)